<DOC>
	<DOCNO>NCT01893268</DOCNO>
	<brief_summary>This prospective , observational study ass effectiveness safety Avastin ( bevacizumab ) 1st line therapy elderly patient advance non-squamous non-small cell lung cancer clinical practice . Therapy Avastin standard chemotherapy administer accord treat physician . Data collect approximately 4 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; = 65 year age Diagnosis advance non squamous NonSmall Cell Lung Carcinoma ( nsNSCLC , stage IIIB IV ) physician decide initiate treatment Avastin combine chemotherapy 1st line therapy Having receive oral write information study , sign write consent form Participation cancer clinical trial investigational medicinal product study Patient previously treat Avastin Patient supervision guardianship</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>